Tatsuhiko joined UntroD Capital Japan, which operates the Real Tech Fund, in 2025. Since October 2026, he has served as Director, Real Tech Fund.

Prior to joining the firm, he was engaged in drug discovery for over 20 years through research roles at Takeda Pharmaceutical Company and other organizations, as well as investment activities at a venture capital firm. At Takeda, he launched the orexin-2 receptor agonist program—therapeutics for narcolepsy and related disorders—under the company’s internal startup initiative. He led the establishment of Target Product Profile (TPP) and Target Research Profile (TRP), guided the creation of development candidates, and oversaw the development of biomarker detection devices, laying the foundation for Takeda’s orexin franchise.

Ph.D., Graduate School of Engineering, Osaka University (2004).